Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JM, Scherr DS, Sboner A, Tagawa ST, Molina AM, Elemento O, Nanus DM, Faltas BM.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):194-200. doi: 10.6004/jnccn.2018.7264.

PMID:
30865916
2.

Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.

Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, Doñate F, Kollmannsberger CK.

Clin Cancer Res. 2018 Sep 15;24(18):4399-4406. doi: 10.1158/1078-0432.CCR-18-0481. Epub 2018 May 30.

PMID:
29848572
3.

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.

Molina AM, Hutson TE, Nosov D, Tomczak P, Lipatov O, Sternberg CN, Motzer R, Eisen T.

Eur J Cancer. 2018 May;94:87-94. doi: 10.1016/j.ejca.2018.02.009. Epub 2018 Mar 20.

4.

Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer VW, Robinson BD, Park K, Cyrta J, Tagawa ST, Kossai M, Fontugne J, Kim R, Sigaras A, Rao R, Pancirer D, Faltas B, Bareja R, Molina AM, Nanus DM, Rajappa P, Souweidane MM, Greenfield J, Emde AK, Robine N, Elemento O, Sboner A, Demichelis F, Beltran H, Rubin MA, Mosquera JM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00038. Epub 2017 Jun 14.

5.

Evaluation of toxicological endpoints in female zebrafish after bisphenol A exposure.

Molina AM, Abril N, Morales-Prieto N, Monterde JG, Lora AJ, Ayala N, Moyano R.

Food Chem Toxicol. 2018 Feb;112:19-25. doi: 10.1016/j.fct.2017.12.026. Epub 2017 Dec 16.

PMID:
29258955
6.

A multidisciplinary approach for the management of earlier stage renal cell carcinoma.

Molina AM M D.

Urol Oncol. 2018 Jan;36(1):15-16. doi: 10.1016/j.urolonc.2017.09.020. Review.

PMID:
29198585
7.

Recommendations for the Management of Rare Kidney Cancers.

Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A.

Eur Urol. 2017 Dec;72(6):974-983. doi: 10.1016/j.eururo.2017.06.040. Epub 2017 Jul 16. Review.

PMID:
28720391
8.

Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA.

Nat Genet. 2016 Dec;48(12):1490-1499. doi: 10.1038/ng.3692. Epub 2016 Oct 17.

9.

Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.

Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR.

J Clin Oncol. 2016 Nov 10;34(32):3846-3853. doi: 10.1200/JCO.2016.67.9084.

10.

Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?

Molina AM, Hu J, Nanus DM.

J Clin Oncol. 2016 Sep 20;34(27):3235-6. doi: 10.1200/JCO.2016.68.4050. Epub 2016 Aug 15. No abstract available.

PMID:
27528717
11.

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.

Carlo MI, Molina AM, Lakhman Y, Patil S, Woo K, DeLuca J, Lee CH, Hsieh JJ, Feldman DR, Motzer RJ, Voss MH.

Oncologist. 2016 Jul;21(7):787-8. doi: 10.1634/theoncologist.2016-0145. Epub 2016 Jun 10.

12.

Recent advances in the management of renal cell carcinoma.

Molina AM, Nanus DM.

F1000Res. 2016 Mar 23;5. pii: F1000 Faculty Rev-391. doi: 10.12688/f1000research.7935.1. eCollection 2016. Review.

13.

First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.

Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, Cohen LJ.

Cancer Chemother Pharmacol. 2016 Jan;77(1):155-62. doi: 10.1007/s00280-015-2909-2. Epub 2015 Nov 14.

PMID:
26576779
14.

Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.

Sankin A, Hakimi AA, Hsieh JJ, Molina AM.

Front Oncol. 2015 Apr 8;5:67. doi: 10.3389/fonc.2015.00067. eCollection 2015. Review.

15.

Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis.

Bastos DA, Molina AM, Hatzoglou V, Jia X, Velasco S, Patil S, Voss MH, Feldman DR, Motzer RJ.

Clin Genitourin Cancer. 2015 Feb;13(1):59-66. doi: 10.1016/j.clgc.2014.06.002. Epub 2014 Jun 8.

PMID:
25023939
16.

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R, Michaelson MD.

Cancer Chemother Pharmacol. 2014 Jan;73(1):181-9. doi: 10.1007/s00280-013-2339-y. Epub 2013 Nov 5.

17.

Systemic treatment options for untreated patients with metastatic clear cell renal cancer.

Molina AM, Motzer RJ, Heng DY.

Semin Oncol. 2013 Aug;40(4):436-43. doi: 10.1053/j.seminoncol.2013.05.013. Review.

PMID:
23972707
18.

Long-term response to sunitinib therapy for metastatic renal cell carcinoma.

Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ.

Clin Genitourin Cancer. 2013 Sep;11(3):297-302. doi: 10.1016/j.clgc.2013.04.001. Epub 2013 May 24.

19.

Endocrine-active compound evaluation: qualitative and quantitative histomorphological assessment of zebrafish gonads after bisphenol-A exposure.

Molina AM, Lora AJ, Blanco A, Monterde JG, Ayala N, Moyano R.

Ecotoxicol Environ Saf. 2013 Feb;88:155-62. doi: 10.1016/j.ecoenv.2012.11.010. Epub 2012 Dec 6.

PMID:
23219663
20.

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.

Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ.

Cancer. 2012 Apr 1;118(7):1868-76. doi: 10.1002/cncr.26429. Epub 2011 Sep 6.

21.

mTOR inhibitors in advanced renal cell carcinoma.

Voss MH, Molina AM, Motzer RJ.

Hematol Oncol Clin North Am. 2011 Aug;25(4):835-52. doi: 10.1016/j.hoc.2011.04.008. Review.

22.

Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.

Molina AM, Motzer RJ.

Oncologist. 2011;16 Suppl 2:45-50. doi: 10.1634/theoncologist.2011-S2-45. Review.

23.

Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.

Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ.

Am J Clin Oncol. 2011 Oct;34(5):454-9. doi: 10.1097/COC.0b013e3181f47aa4.

24.

Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression.

López-Lago MA, Thodima VJ, Guttapalli A, Chan T, Heguy A, Molina AM, Reuter VE, Motzer RJ, Chaganti RS.

Cancer Res. 2010 Dec 1;70(23):9682-92. doi: 10.1158/0008-5472.CAN-10-2279. Epub 2010 Oct 15.

25.

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.

Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ.

Invest New Drugs. 2012 Feb;30(1):335-40. doi: 10.1007/s10637-010-9491-6. Epub 2010 Aug 14.

26.

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.

Molina AM, Ginsberg MS, Motzer RJ.

Med Oncol. 2011 Dec;28(4):1527-9. doi: 10.1007/s12032-010-9640-y. Epub 2010 Aug 10.

27.

Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma.

Molina AM, Motzer RJ.

Clin Genitourin Cancer. 2008 Dec;6 Suppl 1:S7-13. doi: 10.3816/CGC.2008.s.002. Review.

PMID:
19891124
28.

Targeting renal cell carcinoma.

Motzer RJ, Molina AM.

J Clin Oncol. 2009 Jul 10;27(20):3274-6. doi: 10.1200/JCO.2009.21.8461. Epub 2009 May 18. No abstract available.

PMID:
19451422
29.

Acute effects of microcystins MC-LR and MC-RR on acid and alkaline phosphatase activities and pathological changes in intraperitoneally exposed tilapia fish (Oreochromis sp.).

Atencio L, Moreno I, Prieto AI, Moyano R, Molina AM, Cameán AM.

Toxicol Pathol. 2008 Apr;36(3):449-58. doi: 10.1177/0192623308315356. Epub 2008 Apr 25.

PMID:
18441257
30.
31.

Influence of wine fermentation temperature on the synthesis of yeast-derived volatile aroma compounds.

Molina AM, Swiegers JH, Varela C, Pretorius IS, Agosin E.

Appl Microbiol Biotechnol. 2007 Dec;77(3):675-87. Epub 2007 Oct 16.

PMID:
17938912
32.

Quantitative study of Xanthosoma violaceum leaf surfaces using RIMAPS and variogram techniques.

Favret EA, Fuentes NO, Molina AM.

Microsc Res Tech. 2006 Aug;69(8):684-8.

PMID:
16788991

Supplemental Content

Loading ...
Support Center